Gevork I. Minaskanian
Oprichter bij ADERIS Pharmaceuticals, Inc.
Profiel
Gevork I.
Minaskanian is a Co-Founder and Vice President of Chemistry for ADERIS Pharmaceuticals, Inc. He is an Adjunct Professor of Chemistry at Virginia Commonwealth University.
Prior to joining Aderis, Dr. Minaskanian was Principal Research Scientist of Whitby Research, Inc. (previously Nelson Research and Development).
He received a PhD from Texas Tech University.
Actieve functies van Gevork I. Minaskanian
| Bedrijven | Functie | Begin |
|---|---|---|
ADERIS Pharmaceuticals, Inc.
 ADERIS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ADERIS Pharmaceuticals, Inc. develops and commercializes drugs and pharmaceuticals. It engages in small molecule drug development to treat central nervous system, cardiovascular, and inflammatory disorders. The company was founded by Donald McAfee, Noel Cusack, Gevork I. Minaskanian, and Peter Savasand in 1994 and is headquartered in Hopkinton, MA. | Oprichter | 01-01-1994 |
| Virginia Commonwealth University | Corporate Officer/Principal | - |
Eerdere bekende functies van Gevork I. Minaskanian
| Bedrijven | Functie | Einde |
|---|---|---|
| Whitby Research, Inc. | Corporate Officer/Principal | - |
Opleiding van Gevork I. Minaskanian
| Texas Tech University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
ADERIS Pharmaceuticals, Inc.
ADERIS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ADERIS Pharmaceuticals, Inc. develops and commercializes drugs and pharmaceuticals. It engages in small molecule drug development to treat central nervous system, cardiovascular, and inflammatory disorders. The company was founded by Donald McAfee, Noel Cusack, Gevork I. Minaskanian, and Peter Savasand in 1994 and is headquartered in Hopkinton, MA. | Health Technology |
| Whitby Research, Inc. |
